| 618.86 12.36 (2.04%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 733.59 | 1-year : | 856.84 |
| Resists | First : | 628.08 | Second : | 733.59 |
| Pivot price | 590.7 |
|||
| Supports | First : | 582.62 | Second : | 554.53 |
| MAs | MA(5) : | 614.88 |
MA(20) : | 586.02 |
| MA(100) : | 543.29 |
MA(250) : | 499.37 |
|
| MACD | MACD : | 11 |
Signal : | 7.1 |
| %K %D | K(14,3) : | 81  |
D(3) : | 84.8 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 628.08 | Low : | 385.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TMO ] has closed below upper band by 12.1%. Bollinger Bands are 54.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 622.67 - 625.74 | 625.74 - 628.85 |
| Low: | 597.37 - 600.54 | 600.54 - 603.75 |
| Close: | 613.72 - 618.79 | 618.79 - 623.92 |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Fri, 09 Jan 2026
Thermo Fisher (TMO) stock jumps as Stifel lifts target to $700; earnings next - TechStock²
Thu, 08 Jan 2026
How The Narrative Around Thermo Fisher Scientific (TMO) Is Shifting After Q3 And New Forecasts - Yahoo Finance
Wed, 07 Jan 2026
Strategy To YieldBoost Thermo Fisher Scientific To 3.1% Using Options - Nasdaq
Wed, 07 Jan 2026
Thermo Fisher Scientific (TMO) Valuation Check As New Obesity Registry And Key Updates Draw Investor Focus - Yahoo Finance
Tue, 06 Jan 2026
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report? - Finviz
Tue, 06 Jan 2026
Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference - PharmiWeb.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 376 (M) |
| Shares Float | 375 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 92.8 (%) |
| Shares Short | 5,090 (K) |
| Shares Short P.Month | 5,460 (K) |
| EPS | 17.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 135.78 |
| Profit Margin | 15 % |
| Operating Margin | 19.2 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 13.1 % |
| Qtrly Rev. Growth | 4.9 % |
| Gross Profit (p.s.) | 48.17 |
| Sales Per Share | 116.41 |
| EBITDA (p.s.) | 28.85 |
| Qtrly Earnings Growth | 0.5 % |
| Operating Cash Flow | 7,650 (M) |
| Levered Free Cash Flow | 4,700 (M) |
| PE Ratio | 35.77 |
| PEG Ratio | 0 |
| Price to Book value | 4.55 |
| Price to Sales | 5.31 |
| Price to Cash Flow | 30.39 |
| Dividend | 0.43 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|